Celgene (CELG) Tops Q1 EPS by 3c; Boosts Lower End of Outlook

Celgene (NASDAQ: CELG) reported Q1 EPS of $1.32, $0.03 better than the analyst estimate of $1.29. Revenue for the quarter came in at $2.51 billion versus the consensus estimate of $2.59 billion.

GUIDANCE:

Celgene sees FY2016 EPS of $5.60-$5.70, versus prior guidance of $5.50-$5.70 and the consensus of $5.68. Celgene sees FY2016 revenue of $10.75-11 billion, versus prior guidance of $10.5-11 billion and the consensus of $11.12 billion.

“Our global teams generated excellent first quarter results and our strong operating momentum makes us confident that we will achieve or exceed our ambitious 2016 goals,” said Mark Alles, Chief Executive Officer of Celgene. “We are driving long-term value creation through the continued advancement of our innovative pipeline with significant clinical data expected over the next two years.”

For earnings history and earnings-related data on Celgene (CELG) click here.

You May Also Be Interested In

• IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
• Teradyne (TER) Tops Q1 EPS by 18c
• Meritage Homes Corporation (MTH) Tops Q1 EPS by 151c; offers guidance